Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + bevacizumab + pyrotinib
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination therapy consisting of three anti-cancer agents: anlotinib, bevacizumab, and pyrotinib. Pyrotinib is an irreversible dual pan-ErbB receptor tyrosine kinase inhibitor that targets EGFR (HER1), HER2, and HER4. It works by binding competitively to the ATP binding domain of the EGFR family, inhibiting phosphorylation of tyrosine kinase and blocking downstream RAS/RAF/MEK/MAPK and PI3K/AKT signaling pathways, thereby inhibiting tumor cell growth. Pyrotinib was developed in China and received conditional approval there for use in combination with capecitabine for HER2-positive advanced or metastatic breast cancer in patients previously treated with anthracycline or taxane chemotherapy.
- Other names
- BLTNIrenePyrotinib maleatePyrroltinib maleate
02
Targets
EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)FGFR (FGFR family)VEGFR4 (Vascular endothelial growth factor Receptor-3)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on anlotinib + bevacizumab + pyrotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + bevacizumab + pyrotinib.